The Significance of the J-Curve in Hypertension and Coronary Artery Diseases

The J-curve effect describes an inverse relation between low blood pressure (BP) and cardiovascular complications. This effect is more pronounced in patients with preexisting coronary artery disease (CAD), hypertension or left ventricular hypertrophy (LVH). The recent large clinical outcomes trials have observed a J-curve effect between a diastolic BP of 70-80 mmHg as well as a systolic BP <130 mmHg. The J-curve phenomenon does not appear in stroke or renal disease. This is because the coronary arteries are perfused during diastole, but the cerebral and renal perfusion mainly occurs in systole. Therefore, caution should be taken to maintain the diastolic blood pressure (DBP) at minimum of 70 mmHg and possibly to maintain the DBP between 80-85 mmHg in patients with severe LVH, CAD or vascular diseases. BP control in high-risk elderly patients should be carefully done as undergoing aggressive therapy to lower the systolic blood pressure below 140 mmHg can cause cardiovascular complications due to the severely reduced DBP and increased pulse pressure.

[1]  G. Panjrath,et al.  The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? , 2009, Journal of the American College of Cardiology.

[2]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[3]  L. Ruilope,et al.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.

[4]  R. Langer,et al.  Blood pressure change and survival after age 75. , 1993, Hypertension.

[5]  J. Goodwin,et al.  Clinical significance of falling blood pressure among older adults. , 2001, Journal of clinical epidemiology.

[6]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[7]  P. Kowey,et al.  Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? , 1996, JAMA.

[8]  I. Stewart.  RELATION OF REDUCTION IN PRESSURE TO FIRST MYOCARDIAL INFARCTION IN PATIENTS RECEIVING TREATMENT FOR SEVERE HYPERTENSION , 1979, The Lancet.

[9]  J. Buring,et al.  Development of Predictive Models for Long-Term Cardiovascular Risk Associated With Systolic and Diastolic Blood Pressure , 2002, Hypertension.

[10]  I. Salti,et al.  PHENYTOIN IN BENIGN INSULINOMA , 1976, The Lancet.

[11]  M. Guazzi,et al.  Upward Shift of the Lower Range of Coronary Flow Autoregulation in Hypertensive Patients With Hypertrophy of the Left Ventricle , 1991, Circulation.

[12]  J. Cutler,et al.  Blood Pressure and Mortality Among Men With Prior Myocardial Infarction , 1995 .

[13]  Giuseppe Mancia,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2009, Blood pressure.

[14]  R. Bellamy,et al.  Diastolic Coronary Artery Pressure‐Flow Relations in the Dog , 1978, Circulation research.

[15]  R. Tilvis,et al.  Determinants and significance of declining blood pressure in old age. A prospective birth cohort study. , 1998, European heart journal.

[16]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[17]  S. Bangalore,et al.  J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. , 2010, European heart journal.

[18]  T. Lumley,et al.  Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. , 2001, Archives of internal medicine.

[19]  A. Nissinen,et al.  Change in blood pressure and 5‐year risk of coronary heart disease among elderly men: the Finnish cohorts of the Seven Countries Study , 1994, Journal of hypertension.

[20]  C. Bulpitt,et al.  On-treatment diastolic blood pressure and prognosis in systolic hypertension. , 2007, Archives of internal medicine.

[21]  C. Mulrow,et al.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? , 1991, JAMA.

[22]  M. Marcus,et al.  The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. , 1988, Circulation.

[23]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[24]  Bernard De Bruyne,et al.  Pitfalls in Coronary Pressure Measurement , 2000 .

[25]  J. Cruickshank,et al.  BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE , 1987, The Lancet.

[26]  S. Yusuf,et al.  Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study , 2009, Journal of hypertension.

[27]  W. Cushman,et al.  The role of diastolic blood pressure when treating isolated systolic hypertension. , 1999, Archives of internal medicine.